Experience with use of recombinant activated factor VII

Journal of Clinical Pharmacy and Therapeutics

Volumn 27, Issue 2, 2002, Pages 133-138

  Divanon, F ^a,b   Hecquard, C ^a   Borel Derlon, A ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b CHU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADULT; AGED; ARTICLE; BLEEDING; CASE REPORT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE;

ADULT; AGED; ANTIBODY FORMATION; FACTOR VII DEFICIENCY; FACTOR VIIA; FEMALE; HEMOPHILIA A; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED;

EID: 0036247867     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2002.00394.x     Document Type: Article

References (38)

1. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
2. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII
3. Recombinant factor VIII for the treatment of previously untreated patients with haemophilia. Safety, efficacy, and development of inhibitors
4. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
5. Prevalence of factor IX inhibitors among patients with haemophilia B: Results of a large-scale North American survey
6. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors
7. Acquired haemophilia
8. Overall experience with NovoSeven
9. Treatment of factor VIII inhibitors
10. Factor VIII inhibitors
11. Inhibitors in hemophilia patients: Current status and management
12. Comparison of anti-human and anti-porcine factor VIII inhibitor levels in 63 patients with severe haemophilia A
13. Adverse effects of treatment with porcine FVIII
14. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: A review of US clinical studies 1987-90
15. Cytotoxic suppression of acquired factor VIII: C inhibitors
16. Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII: C inhibitors
17. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study
18. Clinical experience with recombinant factor VIIa
19. Clinical experience with activated factor VII: Focus on safety aspects
20. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
21. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
22. Recombinant factor VIIa: A new treatment of haemophilia
23. Experiences with continuous infusion of recombinant activated factor VII
24. Management and monitoring of recombinant activated factor VII
25. Feasibility of using recombinant factor VIIa in continuous infusion
26. Safety, efficacy and lessons from continuous infusion with rFVIIa
27. Acute hemarthroses: The benefits of early versus late treatment with recombinant activated factor VII
28. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia
29. A patient with Glanzmann thrombasthenia and epistaxis successfully treated with recombinant factor VIIa
30. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa
31. Recombinant factor VIIa in severe uremic bleeding
32. NovoSeven as a universal haemostatic agent
33. Use of recombinant factor VIIa (NovoSeven) in the treatment of two patients with type III von Willebrand's disease and an inhibitor against von Willebrand factor
34. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience
35. Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies
36. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study
37. Fatal myocardial necrosis associated with prothrombin-complex-concentrate therapy in hemophilia A
38. Thrombogenicity associated with factor IX complex concentrates